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IL-17F is known to be involved in many inflammatory diseases, but its role in skin diseases has not been fully
examined. Because IL-8 is involved in many skin diseases such as psoriasis, we investigated the production of
IL-8 in normal human epidermal keratinocytes (NHEKs) stimulated by IL-17F, tumor necrosis factor-a (TNF-a),
IL-17A, and control using real-time PCR and ELISA. The results showed that IL-17F induced production of IL-8 in
NHEKs in a time-dependent manner. Interestingly, the amounts of IL-8 stimulated by IL-17F were much higher
than those stimulated by TNF-a or IL-17A. Next, we confirmed that selective mitogen-activated protein kinase
kinase inhibitors significantly inhibited IL-17F-induced IL-8 production. Moreover, mouse skin intradermally
injected with IL-17F expressed high level of IL-8 mRNA and induced ERK1/2 phosphorylation. Histological
examination of mouse skin that was injected with IL-17F revealed marked neutrophilia in dermis and the
infiltration was significantly inhibited by anti-IL-8 antibody. Finally, IL-17F expression in skin biopsy samples from
psoriasis patients were examined by western blotting and ELISA. IL-17F was upregulated in lesional psoriatic
skin compared with nonlesional skin. These results indicate that IL-17F may be involved in psoriasis via, in part,
the activation of ERK1/2 and the induction of IL-8 in keratinocytes.
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INTRODUCTION
Psoriasis is a chronic inflammatory skin disorder and is now
recognized to be mediated in part by immune alterations.
Psoriatic plaques are histologically recognized by typical
patterns of abnormal epidermal hyperplasia and differentia-
tion (Gottlieb et al., 2005). In the past 20 years, it has become
clear that these epidermal changes are secondary to robust
immune activation within psoriatic plaques mediated by
cytokine and chemokine release by activated inflammatory
cells including T cells and neutrophils (Nickoloff et al., 2007;
van Beelen et al., 2007). On the basis of the biochemical
analyses and in vitro studies, it has become evident that IL-8
greatly contributes to the major pathologic changes seen in
psoriasis (Sticherling et al., 1991; Takematsu and Tagami,
1993; Duan et al., 2001). However, its biological mechan-
isms remain incompletely defined.
IL-17F is involved in tissue inflammation by inducing the
release of proinflammatory and neutrophil-mobilizing cyto-
kines (Hymowitz et al., 2001; Kawaguchi et al., 2001; Starnes
et al., 2001). Furthermore, it has been documented that Th17
cells, which produce IL-17A and IL-17F, develop via
signaling pathways that are independent of those required
for Th1 or Th2 cells (Steinman, 2007). Although an increase
of IL-17A has been reported in acute atopic dermatitis (Toda
et al., 2003), allergic contact dermatitis (Albanesi et al., 1999)
and psoriasis (Teunissen et al., 1998; Albanesi et al., 2000;
Zheng et al., 2007), the role of IL-17F in skin diseases has not
yet been fully examined. Therefore, we investigated the
functional role of IL-17F in normal human epidermal
keratinocytes (NHEKs) in this study. Our results showed that
IL-17F may be important in psoriasis.
RESULTS
IL-8 gene expression in NHEKs induced by IL-17F
To examine the expression of the IL-8 gene in NHEKs,
we investigated whether IL-17F increased the expression of
mRNA for IL-8 using quantitative reverse transcription
real-time PCR. The expression of IL-8 mRNA at 24hours was
30- and 37-fold higher than that in the tumor necrosis factor-a
(TNF-a) and IL-17A treated group, respectively (Figure 1a).
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IL-17F induces IL-8 production by NHEKs
We next investigated whether IL-17F-induced IL-8 protein
production by keratinocytes. IL-17F elicited a time-depen-
dent increase of IL-8 protein levels from 4 to 48 hours
compared with TNF-a, IL-17A, and the phosphate-buffered
saline (PBS) control (Figure 1b). The levels of secreted IL-8
were increased further at 48 hours. The amount of IL-8
stimulated by IL-17F at 48 hours was 3.7-fold higher and 8.3-
fold higher than that stimulated by TNF-a and IL-17A,
respectively. These findings demonstrated that the level of
IL-8 protein correlated well with the IL-8 mRNA level. Thus,
the results indicated that IL-17F is a strong inducer of IL-8 in
keratinocytes.
IL-8 gene expression in the mouse skin induced by IL-17F
To further confirm the IL-8 gene expression in the mouse skin
after IL-17F injection, we examined whether IL-17F increased
the expression of mRNA for IL-8 using quantitative reverse
transcription real-time PCR. The expression of IL-8 mRNA
24hours after injection was 2.9-fold higher than that in the
control group (Figure 2).
ERK1/2 is involved in IL-17F-induced IL-8
A recent study has demonstrated the involvement of
extracellular signal-regulated kinase (ERK) 1/2 kinase, but
not P38 or c-Jun N-terminal kinase, in IL-17F- induced IL-8
production by primary bronchial epithelial cells and human
umbilical vein endothelial cells (Kawaguchi et al., 2002).
Therefore, we examined whether activation of ERK1/2 was
necessary for stimulation of IL-8 production in NHEKs. The
NHEKs were preincubated with various concentrations of the
mitogen-activated protein kinase kinase inhibitors, PD98059
and U1026, a p38 inhibitor, SB202190, and a c-Jun N-
terminal kinase inhibitor, SP600125. As demonstrated in
Figure 3, both PD98059 and U0126 partially, but signifi-
cantly inhibited the production of IL-8 in a dose-dependent
manner, whereas pretreatment of the cells with SB202190,
SP600125, and the control (Me2SO) did not affect IL-8
protein release in NHEKs.
Treatment with IL-17F induces ERK1/2 phosphorylation in the
mouse skin
Ear tissue from the IL-17F-treated mice was collected 0.5, 1,
and 2 hours after intradermal injection (100 ng in 50 ml of
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Figure 1. IL-17F induces IL-8 production by NHEKs. (a) IL-8 gene expression
by IL-17F in NHEKs. Total RNA was extracted from the cell lysates 4 and
24hours after stimulation with 100 ngml1 IL-17F, 100 ngml1 TNF-a,
100 ngml1 IL-17A, and PBS control. The levels of mRNA for IL-8 were
calculated as the fold induction compared with the PBS control using real-
time PCR. (b) Analysis of IL-8 production in NHEKs stimulated with IL-17F
(100 ngml1), TNF-a (100 ngml1), IL-17A (100 ngml1), and PBS control.
IL-8 protein release in the supernatant was determined by ELISA as described
in ‘‘Materials and Methods’’. Results represent mean±SEM from at least
three independent experiments. *Po0.05 was considered significant.
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Figure 2. IL-8 gene expression in the mouse skin induced by IL-17F. Ear
tissue from the IL-17F-treated and PBS control mice were collected 24hours
following intradermal injection and total RNA was isolated from each ear
specimen. The primer sequence was as follows: upstream 50-ATGGCTGGG
ATTCACCTCAA-30, downstream 50-AAGCCTCGCGACCATTCTT-30. The
expression of IL-8 mRNA 24hours was 2.9-fold higher than that in the control
group. Results represent mean±SEM from three independent experiments.
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Figure 3. Effect of inhibitors on IL-8 protein production in NHEKs. The cells
were preincubated with varying concentrations of PD98059, U0126,
SB202190, SP600125, or Me2SO vehicle for 1 hour, followed by stimulation
with IL-17F (100 ngml1) for 24 hours. Results represent mean±SEM from
three independent experiments. *Po0.05 was considered significant versus
IL-17F-stimulated cells without addition of inhibitors.
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PBS). Western blot analysis of phosphorylated and total
ERK1/2 was performed on these skin samples. As shown in
Figure 4, the activation of ERK1/2 was seen at 0.5, 1, and
2 hours after injection. These in vitro (Figure 3) and in vivo
experiments (Figure 4) indicate that ERK1/2 signaling
can contribute to the upregulation of IL-17F-induced IL-8
synthesis.
Induction of neutrophil accumulation in mouse skin by IL-17F
injection
To examine the effect of local immune change by IL-17F, we
intradermally injected recombinant mouse (rm) IL-17F,
TNF-a, or IL-17A into mice. Histological examination of H-
E-stained sections showed that the skin of mice injected with
rm IL-17F showed marked infiltration of inflammatory cells in
the dermis (Figure 5a) compared with that seen in the TNF-a
injected mice (Figure 5c), IL-17A mice (Figure 5d), and
control mice (Figure 5e). Higher magnification (Figure 5b)
showed that the skin injected with IL-17F had neutrophil
infiltration with fewer mononuclear cells in the dermis. No
eosinophils were observed in all groups. Furthermore, we
also examined whether anti-IL-8 Ab blocked the infiltration of
inflammatory cells in IL-17F-treated group. As shown in
Figure 5f and g, inflammatory cells in dermis showed
significant but not complete blocking by anti-IL-8 antibody.
These findings suggest that IL-8 released by keratinocytes in
IL-17F-injected skin may be responsible for accumulation of
neutrophils.
Detection of IL-17F in the skin of psoriasis patients
To examine the IL-17F expression in skin disease, we
retrospectively examined skin biopsy samples from psoriasis
patients. A total of 10 biopsy specimens from psoriasis
vulgaris patients were studied to examine the expression of
IL-17F using western blotting analysis. IL-17F protein was
clearly detected in the psoriatic lesional skin compared with
nonlesional skin from the same patients (Figure 6a).
Furthermore, we quantified the IL-17F protein level by ELISA
method. IL-17F level in the psoriatic lesional skin was higher
than in nonlesional psoriatic skin. However, low level of
IL-17F protein was also detected in nonlesional psoriatic
skin (Figure 6b).
DISCUSSION
Several studies demonstrating IL-8 localization in psoriatic
lesions at the mRNA or protein level have suggested that
keratinocytes are a major source of IL-8 (Gillitzer et al., 1991;
Nickoloff et al., 1991; Antilla et al., 1992; Ozawa et al.,
2005). Moreover, Ghoreschi et al. (2003) showed that
improvement of psoriasis correlates with suppression of IL-8
in the skin. IL-17F has been linked to tissue neutrophil
recruitment through the induction of IL-8 (Kawaguchi et al.,
2004). In this study, IL-17F elicited a time-dependent
increase in IL-8 protein, and the findings demonstrated that
the level of IL-8 protein was correlated well with the levels of
IL-8 mRNA. Interestingly, the amount of IL-8 protein at
48 hours was 3.7-fold higher than that of TNF-a. It is well
known that TNF-a is a strong inducer of IL-8 in NHEKs
(Larsen et al., 1989; Barker et al., 1990). In fact, the cytokine
network involved in psoriasis has TNF-a at center stage as a
key primary cytokine involved in the induction and main-
tenance of plaques (Gottlieb et al., 2005). Our study showed
IL-17F is a stronger inducer of IL-8 in comparison to TNF-a.
This provides evidence supporting the role of IL-17F in
inflammatory skin diseases, such as psoriasis, and that IL-17F
is an efficient inducer of IL-8 release by keratinocytes.
Moreover, the production of IL-8 protein stimulated by IL-17F
was also much higher than that stimulated by IL-17A.
Similarly, in cystic fibrosis, in which pathogenesis is
associated with neutrophils and IL-8, the levels of IL-17F
were higher than IL-17A in sputum from the patients
(McAllister et al., 2005). This would indicate that IL-17F
has diverse biological functions compared with IL-17A, even
though both of them are produced by Th17 cells.
We also demonstrated the involvment of ERK1/2 kinase,
but not p38 or c-Jun N-terminal kinase, in IL-17F-induced IL-
8 production in NHEKs and mouse skin. This result is in
agreement with recent observations obtained using primary
bronchial epithelial cells, human umbilical vein endothelial
cells, and human gastric epithelial cells (Kawaguchi et al.,
2002; Sebkova et al., 2004). However, induction of IL-8 was
not completely inhibited by the ERK1/2 kinase inhibitors
PD98059 and U0126, suggesting that additional signaling
pathways are involved in cytokine induction by IL-17F in
keratinocyte. Hwang et al. (2004) reported that IL-17F-
mediated induction of IL-8 may be transduced, in part, via
activation of PI3-kinase/Akt pathway and NF-kB. Further
research will focus on uncovering the signaling pathway of
IL-17F.
It has been reported that there is an in vivo role of human
IL-17F in recruiting neutrophils into the pulmonary mucosa in
mice after adenoviral gene transfer (Hurst et al., 2002), and
IL-17F stimulated bronchial epithelial cells to produce IL-8
(Kawaguchi et al., 2001; Oda et al., 2005). In our study, the
mouse skin intradermally injected with rm IL-17F showed
marked neutrophil infiltration in the dermis with fewer
mononuclear cells. Moreover, the neutrophil infiltration
was significantly blocked by anti-IL-8 antibody. These
findings suggest that neutrophilia in the dermis was induced
via induction of IL-8 in keratinocytes stimulated by IL-17F.
Thus, the IL-17F-IL-8 axis may be important in the
pathophysiologic events in psoriasis.
In summary, we have investigated the effect of IL-17F in
skin disease using in vitro and in vivo approaches. Recent
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Figure 4. Treatment with IL-17F induces ERK1/2 phosphorylation in the
mouse skin. Ear tissue samples collected at 0.5, 1, and 2hours following
IL-17F injection (100 ng in 50 ml of PBS) were prepared. Western blot analysis
of phosphorylated and total ERK1/2 was performed on these skin samples.
The activation of ERK1/2 was seen at 0.5, 1, and 2 hours after injection.
The results shown are representative of three separate experiments.
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studies suggest that Th17 cytokines are important in psoriasis
(Blauvelt, 2007; Nickoloff, 2007; Zaba et al., 2007; Haider
et al., 2008). Wilson et al. (2007) showed IL-17F mRNA had
significantly higher expression in lesional skin than in
nonlesional or healthy skin. Moreover, they explained that
low level of IL-17F was detected in psoriatic nonlesional skin.
Our study confirmed this finding by protein level. Further
investigation of IL-17F may open new avenues for the
development of biological therapies for psoriasis.
MATERIALS AND METHODS
All experiments were conducted in accordance with the Declaration
of Helsinki Principles.
Cell culture and human recombinant IL-17F
NHEKs were purchased from Cambrex Bio Science Walkersville Inc.
(Walkersville, MD) and used between passages 2 and 3. The cells
were maintained in accordance with the supplier’s protocols.
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Figure 5. Histologic examination. Histopathological findings 48 hours after intradermal injection of (a) IL-17F, (c) TNF-a, (d) IL-17A, and (e) PBS control.
Bar¼100 mm. (b) High magnification of a. Infiltrating cells in the dermis consisted mainly of neutrophils (arrow). Bar¼ 50mm. (g) A cell count was performed as
described in ‘‘Materials and Methods’’, and the density of dermal infiltration was expressed as mononuclear cells, neutrophils, eosinophils, and total number of
cells. No infiltrating eosinophils were seen in both the IL-17F-treated and other groups. The number of neutrophils in the dermis was significantly increased by
injection of recombinant mouse IL-17F compared with the control group (*Po0.05) and the inflammatory cells in the dermis were significantly but not
completely blocked by anti-IL-8 antibody (*Po0.05) (f, g). Bar¼ 100mm.
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Figure 6. IL-17F protein in the skin of psoriasis patients. (a) Representative
results from analysis of IL-17F protein production in the nonlesional and
lesional skin of psoriasis patients. Skin specimens were homogenized and the
supernatants were examined by western blotting. (b) Protein level of IL-17F in
the psoriatic lesional skin was higher than in nonlesional psoriatic skin
(*Po0.05). Low level of IL-17F protein was also detected in nonlesional
psoriatic skin. The results were expressed as the mean±SEM (n¼ 5). *Po0.05
was considered significant.
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NHEKs were grown using a KGM-2 Bullet Kit (Cambrex Bio Science
Walkersville Inc.). Human recombinant IL-17F was generated as
reported previously (Kawaguchi et al., 2001). Endotoxin levels were
tested by using Kinetic-QCL Chromogenic Limulus amebocyte lysate
(Bio Whittaker, Walkersville, MD), but were undetectable. The cells
were treated with IL-17F, TNF-a (R&D Systems, Minneapolis, MN),
IL-17A (R&D Systems), or the same volume of PBS for various time
periods.
Animals
Female BALB/c mice were obtained from the Sankyo Laboratory
(Saitama, Japan) and used at 8–10 weeks of age. Five mice were
used in each experimental group, and each experiment was repeated
at least three times. The animal protocol was approved by
the institutional Animal Care and Use Committee of Showa
University.
Treatment with IL-17F
To examine the effect of local administration of IL-17F to the mouse
skin, we injected rm IL-17F (100 ng in 50ml of PBS) (R&D Systems)
intradermally into one side of each ear of the mouse using a 30-
gauge needle. An equal volume of PBS was injected into the ears of
the control group. In some experiments described below, rmTNF-a
(100 ng in 50 ml of PBS), rm IL-17A (100 ng in 50 ml of PBS), rm IL-17F
plus anti-human IL-8 antibody (100 ng rm IL-17F and 100ng anti-
human IL-8 Ab in total 50 ml of PBS) (all R&D Systems) were also
intradermally administrated. The mice were anesthetized with
pentobarbital sodium (50mg kg1 IP; Abbott Laboratories, IL).
Histologic examination
Ear tissues from the IL-17F, TNF-a, IL-17A, and control mice were
collected 48 hours after intradermal injection. We also injected anti-
IL-8 antibody to examine whether IL-8 antibody blocked the
infiltration of inflammatory cells by IL-17F. Slides were prepared
for routine histology and stained with hematoxylin and eosin. The
slides were examined by light microscopy and the histological
changes were compared between the groups. The density of the
dermal infiltration was expressed as mononuclear cells, neutrophils,
eosinophils, and total number of cells. A cell count was performed
on each slide in ten random high-power fields with a  40 objective
(net magnification  400) in order to calculate the mean dermal
cellular infiltrate in areas of each ear, as reported previously (Kondo
et al., 1995; Watanabe et al., 2004).
Skin biopsy
We retrospectively reviewed skin biopsies from 10 patients who had
been diagnosed as having psoriasis vulgaris by both dermatologists
and pathologists between 2000 and 2007. All the patients had been
referred to Showa University Hospital. Oval-shaped skin biopsy
samples had been obtained from the lesional area including the
adjacent normal skin. Slides were prepared for routine histology and
stained with hematoxylin and eosin. Moreover, small pieces of skin
from the lesional and normal areas were stored at 70 1C for western
blot analyses and ELISA.
All subjects were unrelated Japanese individuals and gave
written informed consent for use of their samples. The study was
approved by the Ethics Committee of Showa University School of
Medicine.
Quantitative reverse-transcription and real-time PCR
Total RNA was extracted using an acid guanidinium thiocyanate–-
phenol–chloroform method from 1 106 NHEKs cells at 4 and
24 hours after stimulation with 100 ngml1 IL-17F, 100 ngml1
TNF-a, 100 ngml1 IL-17A, and the same volume of PBS as a
control. cDNAs were synthesized from isolated RNA templates with
a High-Capacity cDNA Archive Kit (Applied Biosystems, Tokyo,
Japan). Pre-designed TaqMan probe sets for IL-8 were purchased
from Applied Biosystems. Each probe has a fluorescent reporter dye
(FAM) linked to its 50 end, and a downstream quencher dye (TAMRA)
linked to its 30 end. We used a TaqMan Ribosomal RNA probe,
which is labeled with a fluorescent reporter dye (VIC), as an internal
control. Each reaction was performed in a 25-ml volume containing
2 Universal Master Mix (Applied Biosystems), primers, labeled
probes and 50 ng cDNA. Amplification conditions consisted of 40
cycles of 95 1C for 15 seconds and 60 1C for 1minutes after
incubation at 95 1C for 10minutes. Amplification and fluorescence
measurements were carried out during the elongation step with an
ABI PRISM 7700 Sequence Detection System (Applied Biosystems).
Ear tissue from the IL-17F-treated and PBS control mice were
collected 24 hours following intradermal injection and total RNA
was isolated from each ear specimen with an acid guanidinium
thiocyanate–phenol–chloroform method. The primer sequence for
IL-8 gene evaluation was decided as Heishi et al. (2003) and Inoue
et al. (2007) performed in their experiment using mouse model
(Figure 2). Data are shown as fold induction relative to control cells
treated with PBS. All PCRs were performed in triplicate.
Levels of IL-8 protein
IL-8 protein levels in the collected supernatants of stimulated NHEKs
were determined with a commercially available ELISA kit (R&D
Systems) according to the manufacturer’s instructions. Cell super-
natants were harvested from cultures in the absence or presence of
100 ngml1 IL-17F, 100 ngml1 TNF-a, 100 ngml1 IL-17A, and the
same volume of PBS, 4, 24, or 48 hours after stimulation. The
amount of secreted IL-8 was determined by ELISA. Each supernatant
was analyzed in duplicate.
Effect of inhibitors on the expression of IL-8
For analysis of the effect of kinase inhibitors, the cells were treated in
the presence or absence of the following inhibitors at various doses:
mitogen-activated protein kinase kinase 1/2 inhibitors, PD98059
(Calbiochem, La Jolla, CA) and U0126 (New England Bio Labs,
Beverly, MA); p38 inhibitor, SB202190 (Calbiochem); a c-Jun N-
terminal kinase inhibitor, SP600125 (Calbiochem); and a vehicle
control, dimethyl sulfoxide (Me2SO) for 1 hour before treatment with
IL-17F (100 ngml1). We decided the concentrations of various
kinase inhibitors according to the previous studies (Davies et al.,
2000; Zhu et al., 2006). The cell supernatants were harvested at 4
and 24 hours after stimulation for analysis by ELISA. IL-8 protein
levels in the supernatants were determined as described above.
IL-17F-induced ERK1/2 activation in mouse skin
Ear tissue samples collected at 0.5, 1, and 2 hours following IL-17F
injection (100 ng in 50 ml of PBS) for detection of ERK1/2 were
prepared and homogenized in lysis buffer containing 50mM Tris
(tris(hydroxymethyl)-aminomethane) (pH 7.4), 150mM NaCl, 0.02M
phenylmethlsulfonyl fluoride, 50mgml1 leupeptin, and 50mgml1
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aprotinin (all Sigma, St Louis, MO). Supernatants were collected after
centrifugation (14,000 r.p.m., 20minutes) and stored at 70 1C until
analysis. Chemiluminescence luminol regent (Santa Cruz Biotech-
nology, CA) was used for detection.
Protein analysis for skin samples from psoriasis patients
Skin biopsy samples obtained from psoriasis patients were homo-
genized in lysis buffer. A total of 50 mg of protein per sample was
analyzed by denaturing sodium SDS–PAGE and immunoblotted with
a polyclonal antibody against human IL-17F (MBL, Nagoya, Japan).
IL-17F protein levels in the supernatants were quantified by
commercially available ELISA kit (R&D Systems). Each supernatant
was analyzed in duplicate. Results were expressed as IL-17F
concentration in pg g1 tissue for homogenates.
Data analysis
The statistical significance of differences was determined by analysis
of variance. Data are expressed as the mean±SEM from indepen-
dent experiments. Any difference with P-values of less than 0.05 was
considered significant. When analysis of variance indicated a
significant difference, the Scheffe F-test was used to determine the
difference between groups.
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